STAT July 1, 2024
The Federal Trade Commission is formally investigating Teva Pharmaceuticals after the company refused to remove approximately two dozen patents for asthma and COPD inhalers from a key federal registry.
The agency sent a civil investigative demand requiring Teva to provide information related to the patents listed in the so-called Orange Book, which is maintained by the Food and Drug Administration. The move comes after the FTC late last year began warning Teva and several other companies...
Today's Sponsors
Today's Sponsor